在刚刚开始的2025年,和黄医药的一系列动作都在反复传达一个讯息,即“归核聚焦”。这里牵涉到一个问题,和黄医药的核心业务究竟是什么,又要聚焦到何处?要回答这个问题,需要把时间拨回到本世纪初从头说起。三十年河东,三十年河西当前的和黄医药,已有多款创新药在手,并已取得不错的销售业绩,以至于很多人都不知道,成立初期的和黄医药曾立志于让中药走向世界。时间回溯至2000年,李嘉诚旗下的和记黄埔斥资2亿,成立...
Source Link在刚刚开始的2025年,和黄医药的一系列动作都在反复传达一个讯息,即“归核聚焦”。这里牵涉到一个问题,和黄医药的核心业务究竟是什么,又要聚焦到何处?要回答这个问题,需要把时间拨回到本世纪初从头说起。三十年河东,三十年河西当前的和黄医药,已有多款创新药在手,并已取得不错的销售业绩,以至于很多人都不知道,成立初期的和黄医药曾立志于让中药走向世界。时间回溯至2000年,李嘉诚旗下的和记黄埔斥资2亿,成立...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.